Cargando…
Improving outcomes of liver resection for hepatocellular carcinoma associated with portal vein tumor thrombosis over the evolving eras of treatment
BACKGROUND: The outcomes and management of hepatocellular carcinoma (HCC) have undergone several evolutionary changes. This study aimed to analyze the outcomes of patients who had undergone liver resection for HCC with portal vein tumor thrombosis (PVTT) in terms of the evolving era of treatment. MA...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546954/ https://www.ncbi.nlm.nih.gov/pubmed/34702312 http://dx.doi.org/10.1186/s12957-021-02425-w |
_version_ | 1784590289232461824 |
---|---|
author | Wang, Yu-Chao Lee, Jin-Chiao Wu, Tsung-Han Cheng, Chih-Hsien Lee, Chen-Fang Wu, Ting-Jung Chou, Hong-Shiue Chan, Kun-Ming Lee, Wei-Chen |
author_facet | Wang, Yu-Chao Lee, Jin-Chiao Wu, Tsung-Han Cheng, Chih-Hsien Lee, Chen-Fang Wu, Ting-Jung Chou, Hong-Shiue Chan, Kun-Ming Lee, Wei-Chen |
author_sort | Wang, Yu-Chao |
collection | PubMed |
description | BACKGROUND: The outcomes and management of hepatocellular carcinoma (HCC) have undergone several evolutionary changes. This study aimed to analyze the outcomes of patients who had undergone liver resection for HCC with portal vein tumor thrombosis (PVTT) in terms of the evolving era of treatment. MATERIALS AND METHODS: A retrospective analysis of 157 patients who had undergone liver resection for HCC associated with PVTT was performed. The outcomes and prognostic factors related to different eras were further examined. RESULTS: Overall, 129 (82.1%) patients encountered HCC recurrence after liver resection, and the median time of recurrence was 4.1 months. Maximum tumor size ≥ 5 cm and PVTT in the main portal trunk were identified as the major prognostic factors influencing HCC recurrence after liver resection. Although the recurrence-free survival had no statistical difference between the two eras, the overall survival of patients in the second era was significantly better than that of the patients in the first era (p = 0.004). The 1-, 2-, and 3-year overall survival rates of patients in the second era were 60.0%, 45.7%, and 35.8%, respectively, with a median survival time of 19.6 months. CONCLUSION: The outcomes of HCC associated with PVTT remain unsatisfactory because of a high incidence of tumor recurrence even after curative resection. Although the management and outcomes of patients with HCC and PVTT have greatly improved over the years, surgical resection remains an option to achieve a potential cure of HCC in well-selected patients. |
format | Online Article Text |
id | pubmed-8546954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85469542021-10-26 Improving outcomes of liver resection for hepatocellular carcinoma associated with portal vein tumor thrombosis over the evolving eras of treatment Wang, Yu-Chao Lee, Jin-Chiao Wu, Tsung-Han Cheng, Chih-Hsien Lee, Chen-Fang Wu, Ting-Jung Chou, Hong-Shiue Chan, Kun-Ming Lee, Wei-Chen World J Surg Oncol Research BACKGROUND: The outcomes and management of hepatocellular carcinoma (HCC) have undergone several evolutionary changes. This study aimed to analyze the outcomes of patients who had undergone liver resection for HCC with portal vein tumor thrombosis (PVTT) in terms of the evolving era of treatment. MATERIALS AND METHODS: A retrospective analysis of 157 patients who had undergone liver resection for HCC associated with PVTT was performed. The outcomes and prognostic factors related to different eras were further examined. RESULTS: Overall, 129 (82.1%) patients encountered HCC recurrence after liver resection, and the median time of recurrence was 4.1 months. Maximum tumor size ≥ 5 cm and PVTT in the main portal trunk were identified as the major prognostic factors influencing HCC recurrence after liver resection. Although the recurrence-free survival had no statistical difference between the two eras, the overall survival of patients in the second era was significantly better than that of the patients in the first era (p = 0.004). The 1-, 2-, and 3-year overall survival rates of patients in the second era were 60.0%, 45.7%, and 35.8%, respectively, with a median survival time of 19.6 months. CONCLUSION: The outcomes of HCC associated with PVTT remain unsatisfactory because of a high incidence of tumor recurrence even after curative resection. Although the management and outcomes of patients with HCC and PVTT have greatly improved over the years, surgical resection remains an option to achieve a potential cure of HCC in well-selected patients. BioMed Central 2021-10-26 /pmc/articles/PMC8546954/ /pubmed/34702312 http://dx.doi.org/10.1186/s12957-021-02425-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Wang, Yu-Chao Lee, Jin-Chiao Wu, Tsung-Han Cheng, Chih-Hsien Lee, Chen-Fang Wu, Ting-Jung Chou, Hong-Shiue Chan, Kun-Ming Lee, Wei-Chen Improving outcomes of liver resection for hepatocellular carcinoma associated with portal vein tumor thrombosis over the evolving eras of treatment |
title | Improving outcomes of liver resection for hepatocellular carcinoma associated with portal vein tumor thrombosis over the evolving eras of treatment |
title_full | Improving outcomes of liver resection for hepatocellular carcinoma associated with portal vein tumor thrombosis over the evolving eras of treatment |
title_fullStr | Improving outcomes of liver resection for hepatocellular carcinoma associated with portal vein tumor thrombosis over the evolving eras of treatment |
title_full_unstemmed | Improving outcomes of liver resection for hepatocellular carcinoma associated with portal vein tumor thrombosis over the evolving eras of treatment |
title_short | Improving outcomes of liver resection for hepatocellular carcinoma associated with portal vein tumor thrombosis over the evolving eras of treatment |
title_sort | improving outcomes of liver resection for hepatocellular carcinoma associated with portal vein tumor thrombosis over the evolving eras of treatment |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546954/ https://www.ncbi.nlm.nih.gov/pubmed/34702312 http://dx.doi.org/10.1186/s12957-021-02425-w |
work_keys_str_mv | AT wangyuchao improvingoutcomesofliverresectionforhepatocellularcarcinomaassociatedwithportalveintumorthrombosisovertheevolvingerasoftreatment AT leejinchiao improvingoutcomesofliverresectionforhepatocellularcarcinomaassociatedwithportalveintumorthrombosisovertheevolvingerasoftreatment AT wutsunghan improvingoutcomesofliverresectionforhepatocellularcarcinomaassociatedwithportalveintumorthrombosisovertheevolvingerasoftreatment AT chengchihhsien improvingoutcomesofliverresectionforhepatocellularcarcinomaassociatedwithportalveintumorthrombosisovertheevolvingerasoftreatment AT leechenfang improvingoutcomesofliverresectionforhepatocellularcarcinomaassociatedwithportalveintumorthrombosisovertheevolvingerasoftreatment AT wutingjung improvingoutcomesofliverresectionforhepatocellularcarcinomaassociatedwithportalveintumorthrombosisovertheevolvingerasoftreatment AT chouhongshiue improvingoutcomesofliverresectionforhepatocellularcarcinomaassociatedwithportalveintumorthrombosisovertheevolvingerasoftreatment AT chankunming improvingoutcomesofliverresectionforhepatocellularcarcinomaassociatedwithportalveintumorthrombosisovertheevolvingerasoftreatment AT leeweichen improvingoutcomesofliverresectionforhepatocellularcarcinomaassociatedwithportalveintumorthrombosisovertheevolvingerasoftreatment |